Trademark: 87528946
Word
AZALTIA
Status
Dead
Status Code
606
Status Date
Monday, March 8, 2021
Serial Number
87528946
Mark Type
4000
Filing Date
Friday, July 14, 2017
Published for Opposition
Tuesday, December 5, 2017
Abandoned Date
Monday, March 8, 2021

Trademark Owner History
Allergan Finance, LLC - Owner At Publication

Classifications
5 Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceuticals and medicines for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; Pharmaceutical neuroprotective agents; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body

Trademark Events
Mar 8, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 8, 2021
Abandonment - No Use Statement Filed
Aug 8, 2020
Notice Of Approval Of Extension Request E-Mailed
Aug 7, 2020
Extension 5 Granted
Jul 10, 2020
Extension 5 Filed
Aug 6, 2020
Case Assigned To Intent To Use Paralegal
Jul 10, 2020
Teas Extension Received
Jan 28, 2020
Notice Of Approval Of Extension Request E-Mailed
Jan 24, 2020
Extension 4 Granted
Jan 24, 2020
Extension 4 Filed
Jan 24, 2020
Teas Extension Received
Jul 8, 2019
Assigned To Examiner
Jun 11, 2019
Notice Of Approval Of Extension Request E-Mailed
Jun 7, 2019
Extension 3 Granted
Jun 7, 2019
Extension 3 Filed
Jun 7, 2019
Teas Extension Received
Jan 22, 2019
Notice Of Approval Of Extension Request E-Mailed
Jan 18, 2019
Extension 2 Granted
Jan 18, 2019
Extension 2 Filed
Jan 18, 2019
Teas Extension Received
Jul 21, 2018
Notice Of Approval Of Extension Request E-Mailed
Jul 19, 2018
Extension 1 Granted
Jul 19, 2018
Extension 1 Filed
Jul 19, 2018
Teas Extension Received
Jan 30, 2018
Noa E-Mailed - Sou Required From Applicant
Dec 5, 2017
Official Gazette Publication Confirmation E-Mailed
Dec 5, 2017
Published For Opposition
Nov 15, 2017
Notification Of Notice Of Publication E-Mailed
Oct 30, 2017
Assigned To Lie
Oct 13, 2017
Approved For Pub - Principal Register
Oct 13, 2017
Examiner's Amendment Entered
Oct 13, 2017
Notification Of Examiners Amendment E-Mailed
Oct 13, 2017
Examiners Amendment E-Mailed
Oct 13, 2017
Examiners Amendment -Written
Oct 5, 2017
Assigned To Examiner
Jul 21, 2017
New Application Office Supplied Data Entered In Tram
Jul 18, 2017
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24